What is the prognosis of hyposomatotropism (growth hormone deficiency [GHD])?

Updated: Jan 24, 2019
  • Author: Sunil Kumar Sinha, MD; Chief Editor: Robert P Hoffman, MD  more...
  • Print

The prognosis depends on the underlying etiology of growth hormone (GH) deficiency (GHD). Non-adherence to growth hormone therapy (GHT) ican impact treatment success. Several studies have shown that adherence to growth hormone therapy (GHT) is not optimal; however, the exact rate of nonadherence reported varies considerably. There is growing evidence to suggest that shared decision-making may facilitate patient adherence to GHT, which may positively impact treatment outcomes.​ [35]

Sequelae of hyposomatotropism include the following:

  • Behavioral and educational difficulties

  • Peripheral vascular disease and reduced myocardial function

  • Lean body mass, reduced muscular strength, and reduced exercise capacity

  • Reduced thermoregulation

  • Abnormal metabolism of thyroid hormone

  • Impaired psychosocial well-being

  • Decreased bone mineral content

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!